1.07% 0.0281

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스

Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by ... - Yahoo New Zealand News

Alzamend Neuro Inc (ALZN) Becoming More Attractive for Investors – Knox Daily - Knox Daily

Technical analysis of Alzamend Neuro Inc (ALZN) stock chart patterns – US Post News - US Post News

Quarterly Snapshot: Quick and Current Ratios for Alzamend Neuro Inc (ALZN) – DWinneX - The Dwinnex

Alzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News Summary - Benzinga

Alzamend Neuro Inc [ALZN] Director makes an insider purchase of 1000 shares worth 688.0. – Knox Daily - Knox Daily

Stock Performance Spotlight: Alzamend Neuro Inc (ALZN) Ends the Day at 0.58, Up by 0.57 – DWinneX - The Dwinnex

Alzamend Neuro secures Nasdaq listing extension - Investing.com India

Alzamend Neuro secures Nasdaq listing extension By Investing.com - Investing.com

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel - Investing News Network

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel - Business Wire

Analyzing Structure Therapeutics (NASDAQ:GPCR) & Alzamend Neuro (NASDAQ:ALZN) - Defense World

Alzamend Neuro Unveils Updated Investor Presentation Outlook - TipRanks.com - TipRanks

A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) – Knox Daily - Knox Daily

Alzamend Neuro Announces Initial Closing of Private Placement - Business Wire

Alzamend Neuro Announces Initial Closing of Private Placement - Business Wire

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 55.2% in April - Defense World

Alzamend Neuro Secures Strategic $25M Investment Deal - TipRanks.com - TipRanks

Tech IPO market still dead - AOL

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an ... - Business Wire

EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares - Alzamend Neuro - Benzinga

EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares - Yahoo Finance

Alzamend Neuro halts its equity offering program By Investing.com - Investing.com

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program - Business Wire

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program - Business Wire

Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Mobile Inf - Benzinga

Alzamend Neuro director buys $688 worth of shares By Investing.com - Investing.com

Alzamend Neuro director buys $688 worth of shares By Investing.com - Investing.com

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga

Alzamend Neuro director Milton Ault III buys $304 in shares By Investing.com - Investing.com

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX: - Benzinga

Alzamend Neuro director Milton Ault III acquires $936k in company stock By Investing.com - Investing.com

ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 - InvestorPlace

Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency - TipRanks.com - TipRanks

Alzamend Neuro Secures Funding Through Preferred Stock Sale - TipRanks.com - TipRanks

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Fortress B - Benzinga

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year - Yahoo Finance

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day ... - Markets Insider

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next ... - Business Wire

Alzamend Neuro regains compliance with Nasdaq bid price rule - Investing.com India

Alzamend Neuro Announces Reverse Stock Split - Business Wire

EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder - Yahoo Finance

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued ... - Business Wire

Alzamend targets Phase IIa trial for bipolar treatment candidate - Clinical Trials Arena

We're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate - Yahoo Finance

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 - Business Wire

ALZN과 유사한 종목